Fifth Third Bancorp’s BioXcel Therapeutics BTAI Stock Holding History

Fifth Third Bancorp’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-63	Closed	-$2.53K	–	2510
2023 Q3	$2.53K	Hold	63	–	–	﹤0.01%	2345
2023 Q2	$6.66K	Hold	63	–	–	﹤0.01%	2115
2023 Q1	$18.7K	Hold	63	–	–	﹤0.01%	1852
2022 Q4	$21.5K	Sell	63 -14	-18%	-$3.38K	﹤0.01%	1676
2022 Q3	$14K	Buy	77 +14	+22%	+$3.25K	﹤0.01%	1814
2022 Q2	$13K	Sell	63 -7	-10%	-$1.47K	﹤0.01%	1896
2022 Q1	$23K	Hold	70	–	–	﹤0.01%	1757
2021 Q4	$23K	Hold	70	–	–	﹤0.01%	1808
2021 Q3	$34K	Hold	70	–	–	﹤0.01%	1592
2021 Q2	$32K	Hold	70	–	–	﹤0.01%	1623
2021 Q1	$48K	Hold	70	–	–	﹤0.01%	1447
2020 Q4	$52K	Hold	70	–	–	﹤0.01%	1370
2020 Q3	$48K	Buy	70 +7	+11%	+$5.26K	﹤0.01%	1339
2020 Q2	$53K	Hold	63	–	–	﹤0.01%	1286
2020 Q1	$22K	Buy	+63	New	+$22.6K	﹤0.01%	1498

Other funds holding BTAI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BPA

Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fifth Third Bancorp's BTAI Position: Q4 2023 in Review

Fifth Third Bancorp sold out of BioXcel Therapeutics (BTAI) in Q4 2023, closing a stake of 63 shares — an estimated $2.53K sold.

Fifth Third Bancorp first reported a position in BTAI in Q1 2020 and held it in 15 quarters. The position peaked at $53K in Q2 2020. 73 funds tracked by Wall St. Rank hold BTAI as of Q4 2023.

Fifth Third Bancorp reported no remaining BioXcel Therapeutics position as of Q4 2023 after selling out during the quarter.
Fifth Third Bancorp sold 63 BioXcel Therapeutics shares in Q4 2023, an estimated $2.53K.
Fifth Third Bancorp first reported a position in BioXcel Therapeutics in Q1 2020 and held it in 15 quarters.
Fifth Third Bancorp's BioXcel Therapeutics position peaked at $53K in Q2 2020.
73 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2023.

Based on Fifth Third Bancorp's 13F filing for Q4 2023, filed 19 Jan 2024.